Precigen, Inc.

Is Precigen, Inc. technically bullish or bearish?

As of July 7, 2025, Precigen, Inc. shows a bullish technical trend despite some short-term weakness indicated by the weekly RSI, having outperformed the S&P 500 significantly with a year-to-date return of 239.29% compared to 12.22%.

As of 7 July 2025, the technical trend for Precigen, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, supported by weekly and monthly MACD readings, which are both bullish, and daily moving averages indicating bullish momentum. However, the weekly RSI is bearish, which suggests some short-term weakness. The Bollinger Bands are bullish on a weekly basis and mildly bullish monthly, while the KST is bullish in both timeframes. Dow Theory presents a mixed view with a mildly bearish weekly stance but a mildly bullish monthly outlook. <BR><BR>In terms of performance, Precigen has significantly outperformed the S&P 500 year-to-date with a return of 239.29% compared to the S&P 500's 12.22%, and over the past year, it has returned 265.38% versus the benchmark's 17.14%.

How big is Precigen, Inc.?

As of Jun 18, Precigen, Inc. has a market capitalization of 427.89 million, with net sales of 4.20 million and a net profit of -156.65 million over the latest four quarters. Shareholder's funds are 66.73 million, and total assets amount to 146.54 million.

As of Jun 18, Precigen, Inc. has a market capitalization of 427.89 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4.20 million, while the sum of net profit for the same period is -156.65 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 66.73 million and total assets of 146.54 million.

What does Precigen, Inc. do?

Precigen, Inc. is a biotechnology company focused on developing biologically-based products using synthetic biology, with a market cap of approximately $427.89 million. As of March 2025, it reported net sales of $1 million and a net loss of $54 million.

Overview: <BR>Precigen, Inc. is a biotechnology company that collaborates to create biologically-based products and processes using synthetic biology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -54 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 427.89 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -5.13 <BR>Return on Equity: -542.41% <BR>Price to Book: 27.68<BR><BR>Contact Details: <BR>Address: 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD: 20876 <BR>Tel: 1 301 5569900 <BR>Website: https://www.dna.com/

Should I buy, sell or hold Precigen, Inc.?

Who are in the management team of Precigen, Inc.?

As of March 2022, the management team of Precigen, Inc. includes Executive Chairman Randal Kirk, Lead Independent Director Robert Shapiro, and Independent Directors Cesar Alvarez, Steven Frank, Vinita Gupta, and Fred Hassan. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Precigen, Inc. includes the following individuals:<BR><BR>- Mr. Randal Kirk, who serves as the Executive Chairman of the Board.<BR>- Mr. Robert Shapiro, who is the Lead Independent Director.<BR>- Mr. Cesar Alvarez, an Independent Director.<BR>- Mr. Steven Frank, also an Independent Director.<BR>- Ms. Vinita Gupta, another Independent Director.<BR>- Mr. Fred Hassan, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.